Skip to main navigation Skip to search Skip to main content

Single intravenous dose of oritavancin for treatment of acute skin and skin structure infections caused by gram-positive bacteria: Summary of safety analysis from the phase 3 SOLO studies

  • SOLO I and SOLO II Investigators
  • Duke University
  • Novartis
  • Sharp Healthcare

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Fingerprint

Dive into the research topics of 'Single intravenous dose of oritavancin for treatment of acute skin and skin structure infections caused by gram-positive bacteria: Summary of safety analysis from the phase 3 SOLO studies'. Together they form a unique fingerprint.
Sort by

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science